TV3, RAC1, ABC, World Pharma News, Neuro Science, among other national and international media, have published articles about the research from the Peptides and Proteins Lab at IRB Barcelona. The study in question is inspired on the scorpion venom to deliver medicines to brain. The scientists have modified a peptide from the venom and used it as a shuttle to transport drugs across the barrier that protects the brain.
Link to TV3
Researchers at IRB Barcelona modify chlorotoxin—a small protein present in scorpion venom with blood-brain barrier permeability—to transport drugs into the brain.
The barrier, which protects the brain, prevents drugs used for the treatment of neurological diseases and brain tumours from entering the organ.
The project presented by Ernest Giralt (IRB Barcelona) and Jordi Vila (ISGLOBAL) has been awarded € 260,000.
Of the 214 projects that applied for funding, 36 were selected on the basis of the evaluation of 103 scientists.
This is the third time that the IRB Barcelona researcher has received funding from “La Marató”.
La Razón, TV3, La Sexta, Men's Health and New Atlas, among other local and international media, have published an article about the study done at IRB Barcelona and Vrije Universiteiti Brussel. The study has identified camelid nanobodies able to block EGF, a protein that is abundant in tumour cells and that helps them to proliferate.
Link to TV3
A study done at IRB Barcelona and the Vrije Universiteit Brussel identifies camelid nanobodies able to block EGF, a protein that is abundant in tumour cells and that helps them to proliferate.
The digital newspaper Público and other media have echoed a study headed by the Universitat Autònoma de Barcelona (UAB) and involving researchers from the Chemistry and Molecular Pharmacology Programme at IRB Barcelona that offers a promising advance towards a treatment for Parkinson’s disease,.
Published in the journal PNAS, the study has revealed that a small molecule, called SynuClean-D, disrupts the formation of amyloid fibers of alpha-synuclein—the process that triggers the development of Parkinson’s disease—and reverses the neurodegeneration that ensues.
Jesús Garcia, Salvador Guardiola, Ernest Giralt and Xavier Salvatella...
For the scientific community, the protein POP (prolyl oligopeptidase) is an attractive therapeutic target for the treatment of cognitive and neurodegenerative disorders.
Scientists at IRB Barcelona have developed the first POP inhibitors that are irreversible, selective and brain-permeable.
Europa Press, El Economista, Technology Networks, News Medical, among other national and international media, have published an article about a study headed by IRB Barcelona that provides the first direct evidence of beta-amyloid dimers (two proteins joined together) in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers.
Link to Europa Press
A study headed by IRB Barcelona provides the first direct evidence of beta-amyloid dimers (two proteins joined together) in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers.
Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
The Meet Our Scientists series presents Ernest Giralt, doctor of chemical sciences, who is the head of the Peptides and Proteins laboratory at IRB Barcelona.
In the video "The power of medicinal chemistry", Giralt highlights his interest in deciphering the language used by proteins to interact with each other.